In addition, Sperduto et al. have revealed that EGFR mutations profoundly influenced the survival of patients with BM from lung adenocarcinoma, presenting EGFR-positive patients with the median survival time of 25.1months [11]. The gene discussed is EGFR; the disease is lung adenocarcinoma.